Top Markets
#1 DogBull DogBull +104.72%
#2 Siacoin Siacoin +51.67%
#3 ADO Protocol ADO Protocol +46.19%
#4 MarsCoin MarsCoin +41.08%
#5 UnifAI Network UnifAI Network +39.25%
#6 Useless Coin Useless Coin +22.93%
#7 Magma Finance Magma Finance +21.52%
#8 Ontology Gas Ontology Gas +20.36%
#9 Cash Cat Cash Cat +14.90%
#10 Apertum Apertum +14.61%
Coin of the day
DogBull DogBull
Settings
Language
ENGLISH
Currency
USD
Theme
AP Biosciences Inc AP Biosciences Inc

AP Biosciences Inc

6945
Rank in Stocks #16392
AP Biosciences Inc. is a pioneering clinical-stage biopharmaceutical company... AP Biosciences Inc. is a pioneering clinical-stage biopharmaceutical company dedicated to the research and development of bispecific antibody drugs, aiming to fulfill critical unmet medical needs. Its robust pipeline features several promising candidates: Leading the pack, IBI302 is in Phase III clinical trials for the treatment of neovascular age-related macular degeneration (nAMD). Further along, AP505 is undergoing Phase I clinical trials for various solid tumors. AP203, also in Phase I, is being investigated for non-small cell lung cancer, head and neck squamous cell carcinoma, and esophageal squamous cell carcinomas. In earlier development, AP402 is currently in the pre-clinical research phase, focusing on breast cancer patients. Additionally, AP601 is also in pre-clinical research, targeting a broader spectrum of malignancies including lung cancer, pancreatic cancer, bladder cancer, ovarian cancer, and other solid tumors. Founded in 2013, the company maintains its headquarters in Taipei City, Taiwan.
Share Price
$3.06
Market Cap
$296.40M
Change (1 day)
-2.24%
Change (1 year)
-22.64%
Country
TW
Trade AP Biosciences Inc (6945)

Category

Healthcare
P/E ratio for AP Biosciences Inc (6945)
P/E ratio as of 2026 TTM: 0
According to AP Biosciences Inc latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for AP Biosciences Inc from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 31.44 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 36.85 -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -17.59 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 -23.32 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.